Innate Pharma S.A. (IPHA)
2.13
0.01 (0.47%)
At close: Mar 03, 2025, 12:32 PM
Innate Pharma S.A. Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 | FY06 | FY05 |
| Revenue | 51.9M | 49.64M | 12.11M | 69.77M | 68.97M | 79.89M | 32.63M | 56.16M | 17.91M | 907K | 12.47M | 10.38M | 11.74M | 4.32M | 7.72M | 12.92M | 14.29M | 6.2M | 1.3M |
| Cost of Revenue | 56.02M | 51.66M | 47M | 49.71M | 45.16M | 69.56M | 67M | 48.63M | 29.91M | 12.09M | 7.58M | 6.86M | 1.64M | 3.43M | 3.35M | 2.56M | 2.77M | 2.2M | 944K |
| Gross Profit | -4.12M | -2.02M | -34.89M | 20.07M | 23.82M | 10.34M | -34.37M | 7.53M | -12M | -11.18M | 4.89M | 3.51M | 10.1M | 893K | 4.37M | 10.37M | 11.52M | 3.99M | 356K |
| Operating Income | -12.67M | -11.65M | -47.83M | 1.08M | -27.05M | 5.15M | -39.98M | 7.57M | -10.77M | -19.97M | -2.79M | -3.39M | -7.57M | -13.69M | -15.54M | -11.01M | -9.09M | -7.24M | -6.42M |
| Interest Income | 3.18M | 4.78M | 6.34M | n/a | 1.62M | 1.58M | 1.25M | n/a | 27K | 445K | 244K | 34K | 945K | 541K | n/a | 1.19M | 212K | 1.2M | 280K |
| Pretax Income | -7.57M | -57.97M | -45.48M | -829K | -20.76M | 2.72M | -48.02M | 12.94M | -6.71M | -19.65M | -2.89M | -3.2M | -6.98M | -13.66M | -14.63M | -9.85M | -8.92M | -6.04M | -6.13M |
| Net Income | -7.57M | -99.1M | -59.14M | -63.98M | -20.96M | 3.05M | -48.38M | 12.64M | -6.71M | -19.65M | -2.89M | -3.2M | -6.98M | -13.66M | -14.63M | -9.85M | -8.92M | -6.04M | -6.13M |
| Selling & General & Admin | 11.75M | 22.44M | 25.52M | 18.99M | 49.58M | 19.25M | 16.18M | 9.33M | 5.88M | 12.82M | 10.67M | 9.73M | 9.79M | 7.06M | 10.06M | n/a | n/a | 1.84M | 1.08M |
| Research & Development | 56.02M | 51.66M | 47M | 49.71M | 1.6M | 69.56M | 67M | 48.63M | 29.91M | 22.67M | 15.13M | 13.42M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Expenses | -3.2M | -8.04M | -12.59M | -49.71M | -309K | -14.06M | -10.57M | -9.37M | -7.11M | -19K | 179K | 2K | 7.88M | 32K | 909K | 21.37M | 20.61M | 9.34M | 5.69M |
| Operating Expenses | 64.57M | 66.06M | 59.94M | 18.99M | 50.87M | 74.75M | 72.61M | 48.59M | 28.68M | 8.76M | 7.66M | 6.88M | 17.67M | 14.58M | 19.9M | 21.37M | 20.61M | 11.18M | 6.77M |
| Interest Expense | 640K | 5.32M | 4M | n/a | 204K | 102K | 113K | 124K | 139K | n/a | n/a | 225K | 520K | 509K | n/a | 36K | 39K | 2K | n/a |
| Selling & Marketing Expenses | n/a | 7.96M | 9.53M | 408K | 8.85M | 1.11M | 527K | 450K | 288K | 314K | 283K | 406K | 9.79M | 7.06M | 10.06M | n/a | n/a | 207K | 139K |
| Cost & Expenses | 64.57M | 66.06M | 59.94M | 68.69M | 96.03M | 74.75M | 72.61M | 48.59M | 28.68M | 20.85M | 15.24M | 13.75M | 19.31M | 18.01M | 23.25M | 23.93M | 23.38M | 13.38M | 7.71M |
| Income Tax | n/a | 41.13M | 13.66M | n/a | 206K | -333K | 368K | 301K | 139K | -24K | -51K | -146K | 1.13M | n/a | 46K | n/a | 51K | 1.2M | 286K |
| Shares Outstanding (Basic) | 80.45M | 79.64M | 79.54M | 6.09B | 66.91M | 58.78M | 54.35M | 53.87M | 51.58M | 50.15M | 38.7M | 37.8M | 37.69M | 37.44M | 26.3M | 25.66M | 25.08M | 17.77M | 14.9M |
| Shares Outstanding (Diluted) | 80.45M | 79.64M | 79.54M | 78.93M | 66.91M | 58.78M | 54.35M | 53.87M | 53.4M | 50.15M | 38.7M | 37.8M | 37.69M | 37.44M | 26.3M | 25.66M | 25.08M | 17.77M | 14.9M |
| EPS (Basic) | -0.09 | -1.24 | -0.74 | -0.01 | -0.31 | 0.05 | -0.89 | 0.23 | -0.13 | -0.39 | -0.07 | -0.08 | -0.19 | -0.36 | -0.56 | -0.38 | -0.36 | -0.34 | -0.41 |
| EPS (Diluted) | -0.09 | -1.24 | -0.74 | -0.01 | -0.31 | 0.05 | -0.89 | 0.23 | -0.13 | -0.39 | -0.07 | -0.08 | -0.19 | -0.36 | -0.56 | -0.38 | -0.36 | -0.34 | -0.41 |
| EBITDA | -1.84M | -61.3M | -43.23M | 13.3M | -20.86M | -3.3M | -35.65M | 10.83M | -8.09M | -17.14M | -1.91M | -1.76M | -5.8M | -12.32M | -14.47M | -12.48M | -8.5M | -6.94M | -6.11M |
| Depreciation & Amortization | 5.09M | 4.42M | 4.57M | 12.23M | 16.53M | 7.4M | 4.4M | 3.26M | 2.65M | 2.34M | 880K | 839K | 901K | 1.1M | 1.02M | 539K | 536K | 298K | 301K |